It has been known since 1962 that glucokinase (GK) is an important determinant of rates of hepatic glucose uptake, and knowledge of its likely role as glucoreceptor in glucose-induced insulin release from islet beta cells dates from 1963/1964. (The term glucoreceptor is preferred to glucose sensor and has been used since the 1960s. Sensors transmit information to or through the nervous system whereas receptors transduce external concentration into a cellular response; the latter is more appropriate for the beta-cell response to glucose). Recently important new dimensions have been added to the metabolic role and significance of glucokinase. This work together with the recent discovery of mutations in the GK gene in families with the MODY variant of Type 2 (non-insulin-dependent) diabetes (maturity onset diabetes of the young) has prompted this review.
Historical and general

Discovery of liver glucokinase
Intracellular metabolism of glucose in animal tissues is initiated by phosphorylation of the sugar to glucose 6-phosphate ( Fig. 1) . In all animal tissues except liver and islet beta cells this reaction is catalysed by hexokinase (HK) isoenzymes I, II or III. For these HKs the Km for glucose is in the range 0.01 to 0.1 mmol/1 and is less than 2 % of the fasting blood glucose concentration. In these tissues dependence of rates of glucose metabolism on extracellular glucose concentration is conferred by the activity of plasma membrane glucose transporters (GLUT 1, 3 and 4, depending on tissue [1] ).
The studies of Cahill et al. [2, 3] first showed in 1958 that hepatocytes are freely permeable to glucose and that the rate of intracellular phosphorylation is therefore dependent on glucose concentration over the physiological range (4-9 mmol/1). This pointed to the existence of an HK with a much higher Km for glucose than the values of 0.01-0.1 mmol/1 for HKs known at the time. This enzyme activity (HK IV or GK) was subsequently identified in liver homogenates by Weinhouse and co-workers [4] and the enzyme purified by Sols and colleagues [5, 6] in [1963] [1964] [1965] [1966] . The name glucokinase was adopted, partly in deference to Carl Cori, and partly to distinguish its unique properties amongst HKs viz lower Mr (molecular weight), higher Km for glucose (12 mmol/1), sigmoid glucose concentration-reaction velocity relationship (Hill coefficient 1.6), and absence of inhibition by the reaction product glucose 6-phosphate. GK is not specific for glucose; values for K~ (in mmol/1) and relative V~a~ are glucose (12, 
Discovery of pancreatic islet glucokinase
Studies by Grodsky and co-workers [7] and by Coore and Randle [8] in 1962-1964 first showed that only sugars which are substrates for HKs and for glycolysis elicit insulin release thus suggesting a link between their metabolism and insulin release. These studies also showed that the concentration of glucose required for half-maximum stimulation of insulin release was of the order of 10 mmol/1. Coore and Randle [8] concluded in 1964, on the basis of their findings, that islet beta cells are freely permeable to glucose and contain GK, and that "phosphorylation of glucose in the beta cell may control glucose metabolism and the secretion of insulin" [9] . The findings were 1) D-mannoheptulose inhibits insulin release induced by glucose and mannose but not that induced by tolbutamide [8, 10] 2) D-mannoheptulose inhibits rat or rabbit liver GK (Ki i mmol/1) and HKs [6, 11] and glucose uptake by rat liver [11] 3) phloridzin, D-galactose and 3-0-methyl-D-glucose (inhibitors of glucose-transport) do not inhibit glucose-induced insulin release [7, 8] whereas Dglucosamine which inhibits GK (Ki 0.5 mmol/1) [6] is inhibitory [8] . In 1968 Matschinsky and Ellerman [12] confirmed this conclusion by direct analysis of islet glucose, and the presence of HKs in islet extracts with low and high Km for glucose was shown by them and by Ashcrofl and Randle [12] [13] [14] [15] . The definitive evidence for the presence of GK protein in pancreatic islets was obtained by immuno-blotting and by the detection of mRNA (Iynedjian and co-workers [16, 17] ); by immunocytochemical localisation to islet beta cells [18] ; and by isolation and sequence analysis of full length cDNA by Magnuson, Permutt and colleagues [18] [19] [20] (this latter method has revealed structural differences between liver and islet GKs which are discussed later).
Metabolism of sugars and insulin release
Two glucoreceptor models were proposed in 1968 for the effects of glucose and related sugars on insulin release. The regulator site model envisaged glucose acting directly by an allosteric mechanism (i.e. at a regulator site) to switch a cell signalling system whereas the substrate site model envisaged glucose acting via the substrate site of GK and a metabolic pathway [21] . There was a period (1971) (1972) (1973) Particularly compelling evidence has come from a comparison of glucose and NAG which share a common transporter but are phosphorylated by different kinases. Islet metabolism of each of these sugars was found to be selectively blocked by specific inhibitors (transport inhibitors for NAG; GK inhibitors for glucose). The same pattern of inhibitor specificity was shown to apply to insulin release (reviewed in [24] ). Two residual potential anomalies are the potentiation of glucose-induced release by fructose and the failure of NAG (a GK inhibitor) to inhibit glucose-induced release [28] . The fructose effect is explicable through fructose 1-phosphate activation of GK (see later section). Lack of inhibition by NAG (Ki for GK 40 retool/1 [6] ) is explicable by low transport rates, rapid intracellular removal by NAG kinase and NAG stimulation of insulin release [24, 29] .
Finally there is an hypothesis to explain the mechanism whereby glucose metabolism induces insulin release: namely that enhanced glucose metabolism leads through increased beta cell . The implication is that increased oxidations are driven by ATP turnover, occasioned by increased secretion and synthesis of insulin; and that glucose is oxidised because of activation of the pyruvate dehydrogenase complex effected by Ca 2+ and inhibition of fatty acid oxidation effected by malonyl CoA.
Glucose 6-phosphatase; glucose transporter 2
Consideration of the functional role of GK requires reference to glucose 6-phosphatase and glucose transporter 2 (GLUT 2) (Fig. 1 ). Glucose 6-phosphatase reverses the GK reaction and thus net glucose phosphorylation is the difference between the two opposing reactions. In liver, glucose 6-phosphatase is a membrane system composed of an intralumenal phosphatase and transporters for glucose 6-phosphate, glucose and P~ [33] , and catalyses the terminal reaction in hepatic glucose production. It is also present in islets at high activity [14, 33, 34 ], has been detected by both bio-and immuno-assays, and histochemical evidence reviewed by Waddell and Burchall [33] shows beta-cell location. Islet glucose 6-phosphatase is inhibited by glucose at physiological concentrations [14, 34] . This is of considerable potential importance. It is expected to enhance the sigmoid relationship between glucose concen- . Exons 1-10 are shown by shaded areas. Subsequent studies indicated an alternative exon 1 upstream from the one shown [18] . The human gene is organised in similar fashion except for a third alternative exon i downstream from that shown [39] (i.e. rat has exons 1 a, 1 b; man has exons i a, lb, 1 c) tration and glucose phosphorylation and hence of insulin release, but it is often ignored by reviewers.
GLUT 2 is present both in liver and islets [35] . In liver its high Km presumably allows for sensitive switching between glucose uptake and release. In the islet beta cell the high Km of GLUT 2 presumably facilitates rapid re-equilibration of intra-islet glucose concentration when blood glucose concentration is altered. GLUT 2 protein was unchanged by starvation or streptozotocin diabetes whereas mRNA was decreased -50% by starvation and normalised by refeeding [36] .
Chemistry, genetics and regulation of glncokinase
Structural studies
Only one GK gene is detected in man and rat (chromosome 7 band p 13 in mad [37] ). Isoenzymes are formed by differential splicing of GK mRNA [19, 38] . Amino acid sequences (liver and islet beta-cell GKs) in both species have been deduced mainly from nucleotide sequences of full length cDNA [19, 20, [37] [38] [39] [40] [41] .
Rat liver GKs contain 465 amino acids [39, 40] and the two human liver GK isoenzymes (464 and 466 amino acids) show 97 and 98 % homology with the rat liver enzyme [38] . The two isoenzymes differ from each other in the sequence of 16 N-terminal amino acids as a result of alternative splicing of a 123 base pair cassette exon between liver exons 1 and 2 [38, 41] .
In both rat [17, 19] and man [20, 37] islet beta-cell GKmRNA is longer than its liver counterpart and there is evidence for more than one isoenzyme (alternative splicing) [19] . Comparison of islet and liver cDNAs predicts N-terminal sequence differences in 15 amino acids. In the rat cDNA sequencing studies also show alternative promoters in islet beta cells and liver separated by at least 12 kilobases (kb) in the gene [19] . There is evidence for similar alternative promoters in human liver and islet beta cells [20, 41] . The use of different promoters in the two cell types predicts possible tissue specific regulatory functions (see next section).
Amino acid sequences of GKs show 53 and 33 % homology with the C-terminal domains of rat brain HK I and yeast HK and a high degree of structural conservation at the putative glucose-and ATP-binding domains [39] . The Mr of HKs are approximately twice that of GKs; the glucose 6-phosphate inhibitory site which is absent in GK is in the N-terminal domain of HKs [39] .
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The rat GK gene is 15.5 kb long and consists of 10 exons separated by 9 introns and predicts an mRNA of 2.357 kb excluding the poly A tail [40] (Fig. 2) . Subsequent studies indicated an alternative exon lb upstream from the one shown (la) [19] . The human gene has the same exon/intron organisation except for a third alternative
Regulation of cellular glucokinase concentration
In rat liver, starvation, low carbohydrate diet and insulin deficiency decrease hepatic activity of GK, liver concentrations of GK protein and GKmRNA(s); and increase the concentration of glucose 6-phosphatase [5, 17, 33, 39, [42] [43] [44] . The cDNAs for proteins of the glucose 6-phosphatase system have not yet been cloned. In cultured primary hepatocytes insulin effects a 20-30 fold increase in GK gene transcription; glucagon (cAMP) inhibits GK gene transcription and overrides the action of insulin; whereas ambient glucose concentration is without influence [44] [45] [46] . Insulin may also play a major role in the postnatal induction of hepatic GK and GK mRNA in rats [44] .
In rat islets starvation markedly decreases insulin secretory response to glucose; the effect is reversed by carbohydrate refeeding and reversal is blocked by actinomycin suggesting involvement of transcription [47] . The level of islet GK and GKmRNA remained constant during the fasting-refeeding cycle in [17] . This appeared to exclude effects on transcription of GK gene or translation of GKmRNA but the study of Tiedge and Lenzen [48] showed that starvation of rats decreased beta-cell GKmRNA by 53 % (reversed by refeeding) and in the study of Malaisse et al. [49] starvation decreased islet GK activity by ~ 50 %. Another possible contribution to effects of starvation is mediation by lipids. Intralipid in rats in vivo specifically inhibited subsequent glucose-induced insulin release in perfused pancreas but this required 48 h of infusion [50] . Fatty acyl CoA inhibits GK [51] but this is a rapid effect and perhaps unlikely to be responsible for the longer term intralipid effect.
In studies with rat islets in culture [52, 53] glucose (20 or 30 mmol/1) over i or 7 days as compared with glucose (1 or 3 retool/l) increased glucose-stimulated insulin release, glycolytic flux, GK activity, and GK protein [52] without increasing GKmRNA [53] whereas pyruvate dehydrogenase (PDH) activity and PDH c~-chain mRNA were increased nine-fold [53] . The response of GK to glucose appeared to involve activation of translation or inhibition of GK degradation or both. It has been concluded that insulin plays no part in the regulation of islet GK activity but current evidence does not wholly suffice for such a conclusion. Islets release insulin and released insulin might exert effects through secretory products of other islet cells.
Insulin appears to be the major positive effector of GK activity in liver whereas glucose concentration may fill this role in islet beta cells. Important secondary effects of glucose on the synthesis of other enzymes of glucose metabo-lism in islets seem likely to be involved also in the longer term regulation of glucose-induced insulin release.
Glucokinase regulator protein
In rat liver fructose increases uptake and phosphorylation of glucose and its conversion to glycogen, lactate, CO2 and amino acids (reviewed in [54] ). The mechanism of the fructose effect has been investigated by Dr. E. Van Schaftingen and his colleagues. In an outstanding series of papers [54] [55] [56] [57] [58] [59] they show that hepatic GK is inhibited by fructose 6-phosphate (Ki 40 gmol/1 [59] ), that the effect of fructose 6-phosphate is reversed by fructose 1-phosphate (K0.5 4.4 gmol/1), and that the effects of fructose phosphates require a specific regulatory protein [55] . In liver as in other tissues fructose 6-phosphate and glucose 6-phosphate are held in equilibrium by phosphoglucoisomerase. The inhibition of GK by fructose 6-phosphate is thus an indirect form of product inhibition. In liver fructose is phosphorylated to fructose 1-phosphate by fructokinase thus providing an explanation for the stimulation of glucose phosphorylation by fructose (Fig. 1) .
The regulatory protein is present in pancreatic islets [60] . It exhibits the same properties as in liver and it regulates islet GK in a parallel fashion to liver GK. In rat and mouse islets fructose did not stimulate insulin release in the absence of glucose or at a concentration of glucose giving maximum release (20 mmol/1) but in the presence of a threshold concentration (5.5mmol/1 of glucose) 20 mmol/1 of fructose doubled the rate of insulin release [28] . Islets contain fructokinase [60] and fructose may potentiate glucose-induced insulin secretion through formation of fructose 1-phosphate, activation of GK, and enhanced metabolism of glucose. This is amenable to investigation. Intriguingly a recent study of the metabolic response to fructose in Type 2 diabetic subjects showed that doses of fructose which had little or no significant effect on plasma glucose concentration (15-35 g) increased plasma insulin and C-peptide [61] .
The mechanism of action of the regulatory protein has been published [55, 56] , and a comprehensive list of inhibitory and stimulatory analogues acting through the regulatory protein has also been published [59] .
Regulatory interactions of the hexosamine biosynthesis pathway
Fructose 6-phosphate, which in liver is formed via the GK and phosphoglucoisomerase reactions, is the starting point for the hexosamine biosynthesis pathway (Fig. 1) . Reaction with glutamine, catalysed by glutamine: fructose 6-phosphate amidotransferase (GFAT) gives rise to glucosamine 6-phosphate and other hexosamine products. Evidence has recently been obtained in rat adipocytes that products of the hexosamine biosynthesis pathway may mediate longer term effects of insulin to induce M2 pyruvate kinase, to repress GFAT, and to desensitise the glucose transport system to insulin stimulation [62, 63] . The evidence for involvement of the hexosamine pathway is based upon the simultaneous requirement for glucose, glutamine and insulin; and the ability of glucosamine to E J. Randle: Glucokinase and candidate genes for diabetes replace glutamine and glucose. Whether this pathway may have regulatory functions in other tissues has yet to be established. There is suggestive evidence for its involvement in liver in the longer term regulation of L-type pyruvate kinase and 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase [62] . The outcome of further studies in this pathway are awaited with interest.
Glucokinase and candidate genes for Type 2 diabetes
Type 2 diabetes is almost certainly heterogeneous from the genetic point of view. The high concordance rate amongst identical twins suggests a strong genetic component although environmental factors in pregnancy and infancy are another possibility [64] . The two major pathogenic components are a subnormal plasma insulin concentration, consistently demonstrable after controlling for obesity and blood glucose concentration [65] ; and insulin resistance in respect of insulin-induced hypoglycaemia [66], muscle glycogen synthesis [67] and other aspects of glucose and fatty acid metabolism [68] . There is evidence that subnormal insulin secretory responses are specific for glucose as stimulus and not shared by tolbutamide, arginine, glucagon or ~adrenergic agonists (as reviewed by Robertson [69] ). There is also evidence that the subnormal response to glucose is an adaptive response to chronic hyperglycaemia which may be partially reversed by tolbutamide, salicylate or phentolamine (reviewed in [69, 70] ). Matschinsky pointed out that such observations could have as their basis malfunction of GK in beta cells. This led him to advocate that the GK gene should be examined for mutations in Type 2 diabetes [71] . Population association studies of the GK gene locus between normoglycaemic and Type 2 diabetic American Blacks [72] and Mauritian Creoles [73] have been positive. Mutations have now been recorded in some families with MODY (Type 2 diabetes subtype presenting from the second decade with an autosomal dominant mode of inheritence) [41, [74] [75] [76] ) and in one pedigree thought to have classic Type 2 diabetes [77] but no other mutations have yet been identified in the common variety of the disease.
Glucokinase gene mutations in Type 2 diabetes
Linkage between the GK locus on chromosome 7 p and diabetes was first reported in 16 French families with MODY by Froguel et al. [76] and in a UK family by Hattersley et al. [74] . In the French study a nonsense mutation in exon 7 of the GK gene was identified [GAG (Glu) to TAG (amber termination codon)] [75] together with two further missense mutations in exon 7 (Thr-228--->Met and Gly-261--+Arg) that cosegregate with diabetes [41] . In the UK study a missense mutation in exon 8 was identified (Gly-299--->Arg) [77] . Molecular modelling studies suggest that mutation of Thr-228 may affect GK affinity for ATP and that Gly-261 mutation may affect glucose binding i.e. alteration of enzyme activity is predicted [41] . In both the UK [74] and French kindreds [78] fasting plasma insulin was unchanged whereas insulin secretory responses to glucose were reduced by 50-70 % (plasma insulin and C-peptide measurements). First phase insulin respon-ses were decreased in the UK kindred [74, 79] but not in the French [78, 80] . Insulin sensitivity was normal in the UK kindred. Further studies in French MODY kindreds have revealed additional abnormal conformers which cosegregated with diabetes in exons 4, 6, 7 and 8 and conformers in exon i a and 9 that did not co-segregate with diabetes [81] . In exon 8, 3 missense mutations were identified [Glu-300-+Lys; Glu-300~Gln; Leu-309-->Pro-309]
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There is clear evidence of genetic heterogeneity amongst MODY patients; linkage to glucokinase has been excluded in other pedigrees [74, 76] and other linkage has been reported [83] . Permutt and colleagues in a recent review including unpublished work [84] report a total of 16 GK structural gene mutations in 18 of 32 French white MODY pedigrees. They estimate from the French studies that 55 % of MODY pedigrees may be linked to GK; that MODY may possibly constitute 10-15% of familial Type 2 diabetes but a much smaller proportion of general or late-onset Type 2 diabetes. They estimate also that GK mutations will be rare ( < 1%) in general Type 2 diabetes in white populations, but that estimates for other population groups are much less certain.
Candidate genes for Type 2 diabetes
Current knowledge of beta-cell glucose metabolism in relation to glucose-induced insulin secretion indicates clearly that there are many potential candidate genes for impaired insulin secretory response to glucose. The GK mutations recently described are believed to impair catalytic efficiency at substrate binding sites but there are many other potential sites. These include promoter regions (with potential for differential hepatic and beta-cell expression) and splicing sites; regulatory domains in GK e, g. the binding site for the fructose 6-/fructose 1-phosphate regulatory protein; and regulatory sites within the GK gene and its promoter region e.g. for possible induction by glucose. Likewise the fructose 6-/fructose-l-phosphate GK regulatory protein is an obvious candidate gene. Glucose transporters have received consideration with largely negative findings. GLUT 2 is of particular interest because of its functional role in beta cells. Negative findings have been reported in respect of linkage to Type 2 diabetes in American Blacks [85] and British MODY pedigrees [86] although a positive population association was reported in British Type2 diabetic patients with a strong family history [87] . Mutations in components of islet glucose 6-phosphatase might be relevant to Type 2 diabetes if they result in enhanced activity (e.g. by mutations at the site of glucose inhibition). Hepatic glucose 6-phosphatase deficiency results in hypoinsulinaemic response to glucose [88] , possibly as an adaptive response of islet GK to chronic hypoglycaemia.
The possible role of candidate genes in respect of insulin resistance has thus far been mainly confined to rare examples of insulin receptor gene mutations. Possible links with the main theme of this review have been alluded to in consideration of the likely regulatory role of the 273 hexosamine biosynthetic pathway initiated by the GFAT reaction. Other topics of obvious interest include possible effects of events in utero (e.g. fetal nutrition) on gene expression in later life [64] . 
